{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:49:11Z","timestamp":1792601351964,"version":"4.5.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001167","name":"Larry L. Hillblom Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajpc.2025.101265","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:57:25Z","timestamp":1755845845000},"page":"101265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Identification and management of patients at high-risk for cardiovascular disease in primary prevention"],"prefix":"10.1016","volume":"23","author":[{"given":"Michael","family":"Ahlers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viet","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0684-0655","authenticated-orcid":false,"given":"Pam","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ajpc.2025.101265_bib0001","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jacc.2015.06.1328","article-title":"The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome","volume":"66","author":"Sperling","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"25 Suppl 2","key":"10.1016\/j.ajpc.2025.101265_bib0002","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101265_bib0003","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcct.2017.02.010","article-title":"Clinical indications for coronary artery calcium scoring in asymptomatic patients: expert consensus statement from the society of cardiovascular computed tomography","volume":"11","author":"Hecht","year":"2017","journal-title":"J Cardiovasc Comput Tomogr"},{"issue":"19","key":"10.1016\/j.ajpc.2025.101265_bib0004","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.15450","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement","volume":"316","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ajpc.2025.101265_bib0005","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jacc.2023.07.018","article-title":"Performance of the ACC\/AHA pooled cohort cardiovascular risk equations in clinical practice","volume":"82","author":"Medina-Inojosa","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101265_bib0006","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jcmg.2023.03.008","article-title":"When does a calcium score equate to secondary prevention?: insights from the multinational CONFIRM registry","volume":"16","author":"Budoff","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101265_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/CIRCULATIONAHA.105.580696","article-title":"Distribution of coronary artery calcium by race, gender, and age: results from the multi-ethnic study of atherosclerosis (MESA)","volume":"113","author":"McClelland","year":"2006","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101265_bib0008","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2021.08.019","article-title":"Modeling the recommended age for initiating coronary artery calcium testing among at-risk young adults","volume":"78","author":"Dzaye","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ajpc.2025.101265_bib0009","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101265_bib0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2025.101265_bib0011","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2022.10.004","article-title":"Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: the multi-ethnic study of atherosclerosis (MESA)","volume":"363","author":"Rikhi","year":"2022","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101265_bib0012","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/HYPERTENSIONAHA.122.20189","article-title":"Association of Lp(a) (Lipoprotein[a]) and hypertension in primary prevention of cardiovascular disease: the MESA","volume":"80","author":"Rikhi","year":"2023","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101265_bib0013","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ajpc.2025.101265_bib0014","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"10.1016\/j.ajpc.2025.101265_bib0015","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101265_bib0016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jacl.2022.10.004","article-title":"Lipoprotein(a) and inflammation- pathophysiological links and clinical implications for cardiovascular disease","volume":"17","author":"Simantiris","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101265_bib0017","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.hlc.2020.03.005","article-title":"The prevalence of elevated lipoprotein(a) in patients presenting with coronary artery disease","volume":"29","author":"Oo","year":"2020","journal-title":"Heart Lung Circ"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101265_bib0018","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101265_bib0019","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Collaboration","year":"2009","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101265_bib0020","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"14","key":"10.1016\/j.ajpc.2025.101265_bib0021","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101265_bib0022","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101265_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the multi-ethnic study of atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101265_bib0024","article-title":"Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)","volume":"18","author":"Razavi","year":"2024","journal-title":"Am J Prevent Cardiol"},{"issue":"7","key":"10.1016\/j.ajpc.2025.101265_bib0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.7326\/0003-4819-151-7-200910060-00009","article-title":"C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. preventive services task force","volume":"151","author":"Buckley","year":"2009","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.ajpc.2025.101265_bib0026","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1001\/archinte.165.18.2063","article-title":"High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the third national health and nutrition examination survey","volume":"165","author":"Miller","year":"2005","journal-title":"Arch Intern Med"},{"issue":"25","key":"10.1016\/j.ajpc.2025.101265_bib0027","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.ajpc.2025.101265_bib0028","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajpc.2025.101265_bib0029","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ajpc.2025.101265_bib0030","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.mayocp.2019.01.044","article-title":"Systemic Lupus Erythematosus and increased prevalence of atherosclerotic cardiovascular disease in hospitalized patients","volume":"94","author":"Katz","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101265_bib0031","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ard.2010.143396","article-title":"The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study","volume":"70","author":"Lindhardsen","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ajpc.2025.101265_bib0032","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avi\u00f1a-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.ajpc.2025.101265_bib0033","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014661","article-title":"Heart failure risk associated with rheumatoid arthritis-related chronic inflammation","volume":"9","author":"Ahlers","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101265_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100316","article-title":"Inflammatory bowel disease and atherosclerotic cardiovascular disease in U.S. adults-A population-level analysis in the national health interview survey","volume":"9","author":"Nasir","year":"2022","journal-title":"Am J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.ajpc.2025.101265_bib0035","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database","volume":"31","author":"Mehta","year":"2010","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101265_bib0036","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archdermatol.2009.94","article-title":"Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality","volume":"145","author":"Prodanovich","year":"2009","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101265_bib0037","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0000000000000773","article-title":"The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy","volume":"33","author":"Appleton","year":"2021","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"10.1016\/j.ajpc.2025.101265_bib0038","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.170770","article-title":"Absence of fibrosis and inflammation by cardiac magnetic resonance imaging in rheumatoid arthritis patients with low to moderate disease activity","volume":"45","author":"Bradham","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajpc.2025.101265_bib0039","article-title":"New aspects of the risk assessment guidelines: practical highlights, scientific evidence, and future goals [Internet]","author":"Arps","year":"2019","journal-title":"MedpageToday"},{"issue":"10","key":"10.1016\/j.ajpc.2025.101265_bib0040","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029633","article-title":"Association of normal serum uric acid level and cardiovascular disease in people without risk factors for cardiac diseases in China","volume":"12","author":"Tian","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2025.101265_bib0041","article-title":"Elevated uric acid as a risk factor","volume":"20","author":"Piani","year":"2021","journal-title":"e-J Cardiol Pract"},{"issue":"14","key":"10.1016\/j.ajpc.2025.101265_bib0042","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease: JACC state-of-the-art review","volume":"74","author":"Sarnak","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9731","key":"10.1016\/j.ajpc.2025.101265_bib0043","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ajpc.2025.101265_bib0044","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jacc.2011.07.010","article-title":"Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease","volume":"58","author":"Go","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"9784","key":"10.1016\/j.ajpc.2025.101265_bib0045","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ajpc.2025.101265_bib0046","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"20","key":"10.1016\/j.ajpc.2025.101265_bib0047","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the american heart association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ajpc.2025.101265_bib0048","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ajpc.2025.101265_bib0049","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101265_bib0050","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.ajpc.2025.101265_bib0051","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.jacc.2010.04.060","article-title":"The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"56","author":"Criqui","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101265_bib0052","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/01.CIR.0000112642.63927.54","article-title":"Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study","volume":"109","author":"Resnick","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101265_bib0053","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.300.2.197","article-title":"Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis","volume":"300","author":"Collaboration","year":"2008","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.ajpc.2025.101265_bib0054","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ajpc.2025.101265_bib0055","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"9542","key":"10.1016\/j.ajpc.2025.101265_bib0056","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ajpc.2025.101265_bib0057","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101265_bib0058","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101265_bib0059","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101265_bib0060","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: results from the 3146 patients randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101265_bib0061","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101265_bib0062","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jacl.2018.03.088","article-title":"Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab","volume":"12","author":"Ridker","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"14","key":"10.1016\/j.ajpc.2025.101265_bib0063","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.101265_bib0064","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1631263","article-title":"Retinopathy, neuropathy, and subsequent cardiovascular events in patients with type 2 diabetes and acute coronary syndrome in the ELIXA: the importance of disease duration","volume":"2018","author":"Seferovic","year":"2018","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.ajpc.2025.101265_bib0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2018.03.030","article-title":"Harmony outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics","volume":"203","author":"Green","year":"2018","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.ajpc.2025.101265_bib0066","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.118.033898","article-title":"Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER trial","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.ajpc.2025.101265_bib0067","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ajpc.2025.101265_bib0068","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.ajpc.2025.101265_bib0069","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2025.101265_bib0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ajpc.2025.101265_bib0071","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ajpc.2025.101265_bib0072","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101265_bib0073","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101265_bib0074","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101265_bib0075","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.101265_bib0077","article-title":"Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) Trial","author":"Bohula","year":"2023","journal-title":"Am Heart J [Internet]"},{"key":"10.1016\/j.ajpc.2025.101265_bib0078","author":"Sharp"},{"issue":"21","key":"10.1016\/j.ajpc.2025.101265_bib0081","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101265_bib0082","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life\u2019s essential 8: updating and enhancing the American heart association\u2019s construct of cardiovascular health: a presidential advisory from the American heart association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"issue":"9753","key":"10.1016\/j.ajpc.2025.101265_bib0083","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101265_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101287","article-title":"Coronary artery calcium staging to guide preventive interventions: a proposal and call to action","volume":"3","author":"Maron","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.ajpc.2025.101265_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.06.002","article-title":"LDL cholesterol management simplified in (adults) - lower for longer is better: guidance from the national lipid association","author":"Jackson","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101265_bib0086","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"10.1016\/j.ajpc.2025.101265_bib0087","first-page":"S158","article-title":"9. pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101265_bib0089","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovascular disease","volume":"21","author":"Bhatia","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"19","key":"10.1016\/j.ajpc.2025.101265_bib0090","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.119.045010","article-title":"Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular disease in 2019: the MESA study (multi-ethnic study of atherosclerosis)","volume":"141","author":"Cainzos-Achirica","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101265_bib0091","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamacardio.2020.4939","article-title":"Value of coronary artery calcium scanning in association with the net benefit of aspirin in primary prevention of atherosclerotic cardiovascular disease","volume":"6","author":"Ajufo","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"24","key":"10.1016\/j.ajpc.2025.101265_bib0092","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.ajpc.2025.101265_bib0093","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ajpc.2025.101265_bib0094","first-page":"16","article-title":"A fence or an ambulance","volume":"27","author":"Malins","year":"1913","journal-title":"Bull N Carol State Board Health"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266666772500340X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266666772500340X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:36:24Z","timestamp":1772919384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266666772500340X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":90,"alternative-id":["S266666772500340X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101265","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and management of patients at high-risk for cardiovascular disease in primary prevention","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101265"}}